Amgen (AMGN)

• Market cap: $159B
• 1 day: -1.70%
• 5 days: -0.88%
• 1 month: 1.19%
• 3 months: 3.25%
• 6 months: 9.28%
• Year to date: 13.88%
• 1 year: -9.17%
• 5 years: 18.09%
• 10 years: 89.57%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Employees: 28,000

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 37 [Q4 2024] → 74 (+37) [Q1 2025]

92% more first-time investments, than exits

New positions opened: 246 | Existing positions closed: 128

18% more capital invested

Capital invested by funds: $112B [Q4 2024] → $131B (+$19.6B) [Q1 2025]

2% more funds holding

Funds holding: 2,811 [Q4 2024] → 2,869 (+58) [Q1 2025]

8% more call options, than puts

Call options by funds: $2.74B | Put options by funds: $2.55B

0.82% more ownership

Funds ownership: 77.62% [Q4 2024] → 78.44% (+0.82%) [Q1 2025]

4% less repeat investments, than reductions

Existing positions increased: 1,115 | Existing positions reduced: 1,162

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $280 5% downside
• Avg. target: $308 4% upside
• High target: $328 11% upside

7 analyst ratings

• positive: 2 29%
• neutral: 5 71%
• negative: 0 0%

Piper Sandler David Amsellem	11% upside $328	Overweight Reiterated	27 Jun 2025
Cantor Fitzgerald Carter Gould	3% upside $305	Neutral Reiterated	24 Jun 2025
Guggenheim Vamil Divan	2% downside $288	Neutral Assumed	20 May 2025
Mizuho Salim Syed	5% downside $280	Neutral Maintained	7 May 2025
UBS Trung Huynh	7% upside $315	Neutral Maintained	2 May 2025